6.82
price down icon3.12%   -0.22
 
loading
Q 32 Bio Inc stock is traded at $6.82, with a volume of 392.64K. It is down -3.12% in the last 24 hours and up +74.87% over the past month. Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
See More
Previous Close:
$7.04
Open:
$7.21
24h Volume:
392.64K
Relative Volume:
1.89
Market Cap:
$87.69M
Revenue:
$53.74M
Net Income/Loss:
$29.82M
P/E Ratio:
2.967
EPS:
2.2986
Net Cash Flow:
$-33.54M
1W Performance:
+45.11%
1M Performance:
+74.87%
6M Performance:
+253.37%
1Y Performance:
+270.65%
1-Day Range:
Value
$6.55
$7.80
1-Week Range:
Value
$4.4028
$7.80
52-Week Range:
Value
$1.345
$7.80

Q 32 Bio Inc Stock (QTTB) Company Profile

Name
Name
Q 32 Bio Inc
Name
Phone
781-999-0232
Name
Address
830 WINTER STREET, WALTHAM
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2026-03-10
Name
Latest SEC Filings
Name
QTTB's Discussions on Twitter

Compare QTTB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
QTTB
Q 32 Bio Inc
6.82 87.69M 53.74M 29.82M -33.54M 2.2986
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.34 119.23B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
745.77 78.84B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
700.45 43.35B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.41 41.57B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
284.05 31.51B 5.36B 287.73M 924.18M 2.5229

Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-25-26 Initiated H.C. Wainwright Buy
Feb-11-25 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-11-25 Downgrade Piper Sandler Overweight → Neutral
Dec-11-24 Downgrade Guggenheim Buy → Neutral
Dec-11-24 Downgrade Leerink Partners Outperform → Market Perform
Dec-11-24 Downgrade Raymond James Strong Buy → Outperform
Dec-11-24 Downgrade Wells Fargo Overweight → Equal Weight
Dec-06-24 Initiated BMO Capital Markets Outperform
Oct-24-24 Initiated Raymond James Strong Buy
Sep-11-24 Initiated Wells Fargo Overweight
Jun-17-24 Initiated Guggenheim Buy
May-21-24 Initiated Leerink Partners Outperform
Apr-11-24 Initiated Oppenheimer Outperform
Apr-02-24 Initiated Piper Sandler Overweight
Jul-28-23 Downgrade Robert W. Baird Outperform → Neutral
Feb-22-22 Reiterated BTIG Research Neutral
Feb-22-22 Downgrade Oppenheimer Outperform → Perform
Feb-22-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-02-21 Initiated Stifel Hold
Dec-14-20 Resumed H.C. Wainwright Buy
Aug-11-20 Reiterated H.C. Wainwright Buy
Jun-25-20 Resumed BofA/Merrill Buy
May-13-20 Initiated RBC Capital Mkts Outperform
Mar-16-20 Upgrade Oppenheimer Perform → Outperform
Feb-24-20 Initiated Chardan Capital Markets Buy
Nov-01-19 Initiated Oppenheimer Perform
Sep-10-19 Initiated Robert W. Baird Outperform
Apr-12-19 Initiated Evercore ISI Outperform
View All

Q 32 Bio Inc Stock (QTTB) Latest News

pulisher
Mar 13, 2026

Q32 Bio Hits New HighRegrowth Signals? - RTTNews

Mar 13, 2026
pulisher
Mar 12, 2026

Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo

Mar 12, 2026
pulisher
Mar 12, 2026

FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World

Mar 12, 2026
pulisher
Mar 11, 2026

Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - TipRanks

Mar 11, 2026
pulisher
Mar 10, 2026

H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka

Mar 10, 2026
pulisher
Mar 10, 2026

H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com India

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio Inc. (QTTB) Reports Q4 Earnings - AlphaStreet

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio 2025 Financial Results: Q4 Net Income $57.7M, Revenue $53.7MNews and Statistics - IndexBox

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $4.71 EPS - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio Inc. releases fourth quarter 2025 results and issues corporate update - Traders Union

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio 10-K: $53.7M collaboration revenue drives $29.8M net income - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio: Q4 Earnings Snapshot - KTVB

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Mar 10, 2026
pulisher
Mar 10, 2026

Q32 Bio: Q4 Financial Overview - Bitget

Mar 10, 2026
pulisher
Mar 06, 2026

Q32 Bio Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView

Mar 06, 2026
pulisher
Mar 05, 2026

Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits

Mar 05, 2026
pulisher
Mar 03, 2026

Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab - Defense World

Mar 03, 2026
pulisher
Mar 02, 2026

QTTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026
pulisher
Mar 01, 2026

QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 01, 2026
pulisher
Feb 28, 2026

QTTB PE Ratio & Valuation, Is QTTB Overvalued - Intellectia AI

Feb 28, 2026
pulisher
Feb 28, 2026

FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright - Defense World

Feb 28, 2026
pulisher
Feb 27, 2026

Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Q32 Bio (QTTB) CSO auto-sells 2,815 shares to cover tax bill - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

FY2025 Earnings Forecast for Q32 Bio Issued By HC Wainwright - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright - Defense World

Feb 27, 2026
pulisher
Feb 26, 2026

Analysts Offer Predictions for Q32 Bio FY2029 Earnings - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Q32 Bio (NASDAQ:QTTB) Now Covered by Analysts at HC Wainwright - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

Q32 Bio (QTTB) Price Target Increased by 32.35% to 15.30 - Nasdaq

Feb 25, 2026
pulisher
Feb 25, 2026

HC Wainwright & Co. Initiates Coverage of Q32 Bio (QTTB) with Buy Recommendation - Nasdaq

Feb 25, 2026
pulisher
Feb 25, 2026

H.C. Wainwright initiates Q32 Bio stock coverage with buy rating - Investing.com

Feb 25, 2026
pulisher
Feb 22, 2026

QTTBQ32 BIO INC Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 21, 2026

Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM - MarketBeat

Feb 21, 2026
pulisher
Feb 20, 2026

Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan

Feb 20, 2026
pulisher
Feb 19, 2026

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha

Feb 19, 2026
pulisher
Feb 19, 2026

Point72, Steven A. Cohen disclose 9.9% stake in Q32 Bio (QTTB) - Stock Titan

Feb 19, 2026
pulisher
Feb 18, 2026

Biotech Q32 Bio joins Oppenheimer health conference Feb. 25 webcast - Stock Titan

Feb 18, 2026
pulisher
Feb 17, 2026

Q32 Bio Announces $10.5 Million Registered Direct Offering - TipRanks

Feb 17, 2026
pulisher
Feb 17, 2026

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Q32 Bio Inc has officially signed an agreement to issue and sell approximately 1.7 million shares of common stock. - Bitget

Feb 17, 2026
pulisher
Feb 17, 2026

Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

Q32 Bio Launches $10.5 Million Registered Direct Offering - marketscreener.com

Feb 17, 2026
pulisher
Feb 17, 2026

Q32 Bio announces $10.5 million registered direct offering - marketscreener.com

Feb 17, 2026
pulisher
Feb 14, 2026

Can Q32 Bio Inc. navigate macro headwindsJuly 2025 Big Picture & Safe Swing Trade Setups - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Is Q32 Bio Inc. stock supported by strong cash flows2025 Sector Review & Daily Growth Stock Tips - mfd.ru

Feb 14, 2026
pulisher
Feb 12, 2026

What is the fair value of Q32 Bio Inc. stock nowRate Cut & Community Trade Idea Sharing Platform - mfd.ru

Feb 12, 2026
pulisher
Feb 11, 2026

Will Q32 Bio Inc. benefit from geopolitical trendsIndex Update & Stepwise Entry/Exit Trade Alerts - mfd.ru

Feb 11, 2026
pulisher
Feb 06, 2026

Growth Value: Will Q32 Bio Inc stock benefit from M A2025 Top Decliners & Growth Focused Entry Point Reports - baoquankhu1.vn

Feb 06, 2026
pulisher
Jan 21, 2026

Pullback Watch: Will Q32 Bio Inc benefit from geopolitical trendsTrade Risk Summary & Accurate Buy Signal Alerts - baoquankhu1.vn

Jan 21, 2026

Q 32 Bio Inc Stock (QTTB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Q 32 Bio Inc Stock (QTTB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Morrison Jodie Pope
CEO
Feb 25 '26
Sale
4.51
9,896
44,675
89,104
Violette Shelia M.
Chief Scientific Officer
Feb 25 '26
Sale
4.51
2,815
12,708
55,569
Morrison Jodie Pope
CEO
Dec 02 '25
Sale
3.46
22,506
77,871
99,000
Kalowski Lee
CFO and President
Dec 02 '25
Sale
3.46
9,072
31,395
39,938
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Cap:     |  Volume (24h):